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Background. Histone deacetylases (HDACs) regulate gene expression by changing histone deacetylation status. Neurotoxicity
is one of the major side effects of cisplatin, which reacts with deoxyribonucleic acid (DNA) and has excellent antitumor
effects. Suberoylanilide hydroxamic acid (SAHA) is an HDAC inhibitor with neuroprotective effects against cisplatin-induced
neurotoxicity. Purpose. We investigated how cisplatin with and without SAHA pretreatment affects HDAC expression/activity in
the brain by using 6-([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA) as a positron emission tomography (PET) imaging
agent for HDAC IIa.Materials and Methods. [18F]FAHA and [18F]fluoro-2-deoxy-2-D-glucose ([18F]FDG) PET studies were done
in 24 mice on 2 consecutive days and again 1 week later. The mice were divided into three groups according to drug administration
between the first and second imaging sessions (Group A: cisplatin 2mg/kg, twice; Group B: cisplatin 4mg/kg, twice; Group C:
cisplatin 4mg/kg, twice, and SAHA 300mg/kg pretreatment, 4 times). Results. The 𝐾𝑖 value of [18F]FAHA was increased and the
percentage of injected dose/tissue g (% ID/g) of [18F]FDG was decreased in the brains of animals in Groups A and B.The 𝐾𝑖 value
of [18F]FAHA and % ID/g of [18F]FDG were not significantly different in Group C. Conclusions. [18F]FAHA PET clearly showed
increased HDAC activity suggestive of cisplatin neurotoxicity in vivo, which was blocked by SAHA pretreatment.
1. Introduction
Acetylation and deacetylation on different positions of the N-
terminal tail of core histones by histone acetylases (HATs)
and histone deacetylases (HDACs) change the nucleosomal
conformation of cells [1]. Under normal conditions, the
protein concentration and enzymatic activities of HATs and
HDACs are carefully balanced. Such equilibrium regulates
cellular homeostasis and gene expression to facilitate normal
cell function and activity. However, disrupted equilibrium
with stronger activity in the deacetylase system leads to
transcriptional repression of a diverse set of genes [2, 3].
In recent years, the functional diversity of theHDAC fam-
ily in the nervous system has been elucidated. A strong asso-
ciation between DNA and histones restricts access by tran-
scription factors and therefore represses gene transcription.
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Addition of acetyl groups to histones reduces attractive
forces between positively charged histone proteins and the
negatively charged DNA phosphate backbone, resulting in
a more relaxed and accessible chromatin structure. Histone
modifications cause dynamic changes in chromatin structure
such as transcriptional repression, cell cycle progression, dif-
ferentiation, andDNA replication that help regulate neuronal
gene expression [4–6].
The introduction of cisplatin revolutionized the treatment
of certain cancers, and it is now an important component of
chemotherapy regimens for lung cancer [7], ovarian cancer
[8], head and neck tumors [9], and germ cell tumors [10].
Despite cisplatin’s excellent efficacy, it also has several side
effects including neurotoxicity, nausea, vomiting, depression,
anxiety, visuoperceptual and psychomotor issues, slowed
reaction time, decreased verbal conceptualization, short-
term memory loss, and weakened attention and executive
process [11].
HDAC inhibitors are emerging anticancer agents [12–
14] and promising for the treatment of cerebral ischemia,
spinal muscular atrophy, and neurodegenerative conditions
such as Alzheimer’s disease, Parkinson’s disease, and Hunt-
ington’s disease [6, 15]. HDAC inhibitors have been impli-
cated in transcriptional repression, cell cycle progression,
differentiation, and DNA replication, as well as the response
to DNA damage [16]. Interestingly, some reports have
pointed out that the HDAC inhibitors may be neuropro-
tective against cisplatin-mediated neurotoxicity. Arany et al.
reported that trichostatin A (TSA) restored cAMP response
element binding protein- (CREB-) mediated transcription
after cisplatin activated epidermal growth factor receptor
(EGFR)/Ras/extracellular signal-regulated kinase (ERK) sig-
naling in mouse proximal tubule cells [17]. Dong and col-
leagues proved that TSA and SAHA prevented cisplatin-
induced caspase activation by blocking Bax translocation,
leading to cytochrome c release from the mitochondria.
Their results also indicated that SAHA blocked cisplatin-
induced phosphorylation of the DNA damage response
kinase Chk2, and SAHA suppressed cisplatin-induced p53
activation but enhanced apoptosis in HCT116 colon cancer
cells [18]. Interestingly, Layman reported that systemic SAHA
administration offers almost complete protection against hair
cell loss from acute ototoxic insult (a side effect of cisplatin)
via the increased expression of prosurvival genes Cdkn1a
(p21) and Hspa1a (Hsp70) and decreased expression of the
proapoptosis gene Bcl2l11 (Bim) [19].
Our group has developed the first PET HDAC IIa radiot-
racer, 6-([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA),
that can be used to image whole-body HDAC IIa expression
and tumor activity [20]. We demonstrated that the rapid
[18F]FAHA accumulation in the brains of rats and rhesus
macaques and the rate of [18F]FAHA accumulation were
dose-dependently inhibited by the pan-HDAC inhibitor,
SAHA (vorinostat). Considering the rapid metabolism of
[18F]FAHA to [18F]FACE in blood, we also developed a mul-
ticompartmental pharmacokinetic model with two simul-
taneous blood input functions to estimate the 𝐾𝑖 value
of [18F]FAHA [21, 22]. Significant brain accumulation of
[18F]FAHA was previously confirmed in a mouse model
of NNK (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone)-
induced lung cancer [23] and the baboon brain [24, 25].
These reports indicate the specific interaction of [18F]FAHA
with HDAC 4 and 5 in the nucleus accumbens, amygdala,
hippocampus, andperiaqueductal greymatter (allHDAC IIa-
rich brain regions) [26]. Indeed, [18F]FAHA is the only PET
tracer that measures the levels of HDAC IIa expression and
activity in vivo.
We aimed to investigate (1) whether SAHA attenuates
acute cisplatin-induced neurotoxicity in the brain and (2)
if our novel imaging biomarker [18F]FAHA is suitable to
monitor HDAC IIa activity/expression alterations in the
brain during treatment with cisplatin or other anticancer
drugs.
2. Materials and Methods
2.1. Animals. Eight-week-old male athymic nude mice (𝑛 =
24, Charles River Laboratories) were used in all the studies.
The animals were kept at a room temperature of 25∘C on a
12 h light/dark cycle and had free access to a standard pellet
diet (Lab Diet, Richmond, IN) and tap water. All animal
protocols were approved by the Institutional Animal Care
and Use Committee of the UTMD Anderson Cancer Center
(IACUC Number 03-05-01832).
2.2. Drug Administration. The athymic nude mice (8 weeks,
Charles River Laboratories) were divided into three groups
(8 mice each) according to drug administration: Group A:
intraperitoneal (IP) injections of 0.1mL of cisplatin solution
in saline at a concentration of 2mg/kg cisplatin, twice; Group
B: IP injections of 0.1mL of cisplatin solution in saline at
a concentration of 4mg/kg cisplatin, twice; Group C: IP
injections of 0.1mL of cisplatin solution in saline at a con-
centration of 4mg/kg cisplatin, twice, and SAHA 300mg/kg
(10% DMSO in 0.1mL saline), four times. Two sets of two
SAHA injections each followed by cisplatin injections at 12 h
intervals were given over 5 days. IP drug administration was
performed for 5 days between the first and second [18F]FAHA
and [18F]FDG PET scans (Figure S1).
2.3. Radiosynthesis. We performed [18F]FAHA radiosyn-
thesis as described in our earlier study [20]. The radio-
chemical yield was 20% decay corrected, and specific
activity > 2GBq/𝜇mol at the end of the synthesis.The overall
radiochemical purity was >99%. [18F]FDG was purchased
from Cyclotope Inc. (Houston, TX), and the specific activity
was estimated as >74GBq/𝜇mol.
2.4. Radiolabeled Metabolites in Plasma. As our prelimi-
nary study, we examined the radiolabeled metabolite of
[18F]FAHA in plasma. The protocols for plasma and serum
preparation and analysis were described by Yeh et al. [22].
According to the metabolic analysis procedure, the amount
of blood withdrawn for each time point should be at least
200𝜇L. We therefore used rats instead of mice since it was
difficult to withdraw sufficient blood from the mouse tail
vein.
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Sprague Dawley rats (𝑛 = 6) were used to estimate the
unmetabolized-to-metabolized ratio of [18F]FAHA in plasma
using the following procedure. Selected blood samples from
different time points after [18F]FAHA administration were
collected and centrifuged. The radioactivity concentrations
in whole blood and plasma were counted using a gamma
counter (Cobra, Packard, CT). Plasma was extracted and
mixed with 3x volumes of acetonitrile and analyzed by high-
performance liquid chromatography (HPLC) (Agilent 1100,
Santa Clara, CA; Supelcogel C-610H column, Sigma-Aldrich,
St. Louis,MO)with amobile phase of 35%MeCN/phosphoric
acid in water at 0.6ml/min. Fractions of [18F]FAHA (parent
compound) and [18F]FACE (metabolite) were calculated
for each sample based on the area under each peak. The
total radioactivity in plasma was expressed as percentage of
injected dose/mL (% ID/mL) and plotted against time since
[18F]FAHA injection. The fraction values of [18F]FAHA and
[18F]FACE were calculated based on the results of radio-
HPLC analysis and plotted against time.The average radioac-
tivity concentration ratio (plasma-to-blood) and fraction
results were applied to the PET quantification, which is
described in further detail below.
2.5. PET/CT Imaging. The mice (𝑛 = 24) were anesthetized
with isoflurane (2% in oxygen). [18F]FAHA (day 1) and
[18F]FDG (day 2) PET studies were done on two consecutive
days and repeated 1 week later on a PET/CT scanner Inveon
(Siemens Preclinical Solutions, Knoxville, TN). Food was
removed overnight before [18F]FDG PET studies. Dynamic
[18F]FAHA PET studies were acquired for 30 minutes after
intravenous (IV) administration of [18F]FAHA (7.4MBq, in
100 𝜇L of saline). Static [18F]FDG PET studies for 10min
were acquired 45min after IV administration of [18F]FDG
(7.4MBq, in 100 𝜇L of saline).
[18F]FAHA or [18F]FDG PET images were reconstructed
using a two-dimensional ordered subsets expectation max-
imization algorithm. PET and CT image fusion and image
analyses were performed using Inveon Research Workplace
software (Siemens Preclinical Solutions, Knoxville, TN).
The CT imaging parameters were X-ray voltage of 80 kVp,
anode current of 500 𝜇A, and an exposure time of 300–350
milliseconds for each of the 360 rotational steps. Images were
reconstructed using the Shepp Logan algorithm.
2.6. Imaging Analysis. Awhole-brain region of interest (ROI)
was manually drawn on axial PET/CT coregistration images
acquired 20–30min after injection of [18F]FAHA or 40min
after injection of [18F]FDG. Region placement was by refer-
ence to an MRI rodent brain template (PMOD Technologies,
Zurich, Switzerland) and a rodent brain atlas.
Dynamic [18F]FAHA or static [18F]FDG PET images
were summed using a rigid transformation algorithm and a
normalized mutual method after running a reslicing process
(PMOD Technologies). The regional radioactivity concen-
trations (KBq/mL) of [18F]FAHA or [18F]FDG PET were
estimated from the maximum pixel values within each ROI,
expressed as percentage of injected dose/tissue g (% ID/g).
2.7. Pharmacokinetic Modeling
2.7.1. Simpliﬁed Graphic Analysis: Patlak Plot. The brain and
thoracic aorta time-activity data from the dynamic PET scans
of [18F]FAHA was used for Patlak plot analyses.
𝑅 (𝑡)
𝐶 (𝑡)
=
𝐾𝑖 ∫
𝑡
0
𝐶 (𝑡) 𝑑𝑡
(𝐶) 𝑡
+ 𝑉
0
, (1)
where 𝑡 is time,𝑅(𝑡) is themean count of the brain,𝐶(𝑡) is the
mean count of the blood,𝐾𝑖 is the clearance determining the
rate of entry into the brain, and𝑉
0
is the distribution volume.
The time between injection and the start of the linear
phase in the Patlak plot was 4–6min. Using the data from the
start of the linear phase, an accurate linear fit was observed
from 6–8min up to 18–20min. The slope of the Patlak plot
represents the influx rate constant 𝐾𝑖.
2.7.2. Pharmacokinetic Modeling. A detailed explanation of
the pharmacokinetic model of [18F]FAHA-derived radioac-
tivity has been published previously [22]. Briefly, the time-
activity curve (TAC) of whole blood was measured from
the ROI placed on the carotid artery with the corrected
plasma-to-whole blood radioactivity concentration ratio.
Then, the fractional values of radioactivity concentrations of
[18F]FAHA and [18F]FACE measured from radio-metabolite
analysis (described above) were applied to the image-
derived plasma TAC to obtain fraction-corrected TACs for
[18F]FAHA and [18F]FACE, respectively.
Importantly, we performed a separate dynamic PET
imaging study with [18F]FACE alone to calculate the rate
constants 𝑘1FACE, 𝑘2FACE, and 𝑘3FACE for the rodent. The
dynamic imaging-derived [18F]FACE input function was
corrected for the plasma-to-whole blood ratio andmetabolite
fraction as described above. The TACs of [18F]FACE-derived
radioactivity of brain regions were fitted to the irreversible
two-tissue compartment model to estimate the rate constants
𝑘1FACE, 𝑘2FACE, and 𝑘3FACE.
Subsequently, the rate constants 𝑘1FACE, 𝑘2FACE, and
𝑘3FACE obtained from the dynamic PET/CT imaging study
with [18F]FACE alone were used as fixed rate constants in the
model of [18F]FAHA-derived radioactivity brain accumula-
tion (Figure S2).
Compartmental modeling, pharmacokinetic analyses,
and imaging processing were accomplished using PMOD
3.7 software (PMOD Technologies). [18F]FDG uptake of the
whole brain was expressed as % ID/g.
2.8. Immunohistochemistry (IHC). Paraffin-embedded sec-
tions were cut at 5 𝜇m thickness, deparaffinized, and rehy-
drated. Antigen retrieval was carried out by microwaving in
10mM citrate buffer (pH 6.0) at 100∘C for 10min. Sections
were washed and then incubated in 3% hydrogen peroxidase
for 15min at room temperature, followed by incubation in
blocking solution for 60min at room temperature.
The primary antibodies employed were acetyl-histone
H2A (Lys5), acetyl-histone A2B (Lys20), acetyl-histone A3
(Lys9), and acetyl-histone H4 (Lys8) (all from Cell Signaling
Technology, Danvers, MA). All antibodies were employed at
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a dilution of 1 : 50 and incubated overnight at 4∘C. Biotiny-
lated secondary antibodies and 3,3-diaminobenzidine from
the Vectastain Elite kit (Vector Laboratories, Burlingame,
CA) were used according to the manufacturer’s protocol.
Microscopic evaluations of immunostained sections were
performed using a BX51 microscope equipped with a DP71
digital camera (Olympus, Tokyo, Japan).
A semiquantitative assessment of protein expression was
made based on the number of cells showing nuclear expres-
sion of each AH3 marker over five nonoverlapping micro-
scopic fields (at ×100 microscope objective magnification),
as follows: 0 = absent, less than 5% immunopositive neurons
seen; 1 = rare, 10–20% immunopositive neurons per field; 2
= mild, 20–40% mildly or moderately positive neurons per
field; 3 = moderate, 40–60% moderately or strongly positive
neurons per field; and 4 = strong, more than 80% strongly
positive neurons per field. A percentage score for each case
was calculated as follows: actual rating × 100/maximal score
(i.e., a rating value of 4).
Percentage of positive signal
=
Sum of score of the group
Number of case ×maximal score 4
× 100%.
(2)
2.9. Animal Behavior Test. Open field and 𝑌-maze tests were
performed for Groups B and C, 1 day before the first and
second PET scans.
2.10. Open Field Test. Significant cisplatin neurotoxicity
occurs during or after chemotherapy [27], and cisplatin-
treated mice exhibit less exploratory behavior after treatment
[28]. We tested whether the HDAC inhibitor SAHA could
protect against damage induced by cisplatin.
Locomotor and rearing assessments are widely used to
test rodent exploratory behavior, and both can be measured
in an open field test. The open field was made of plywood
and surrounded by 25 cm high walls. The floor of the open
field was made of black cardboard (𝑙 × 𝑤, 30 × 30 cm) and
divided into 9 squares (3 rows of 3). Each mouse was placed
individually at the center of the apparatus and observed for
5min to record locomotor (number of segments crossed with
the four paws) and rearing activities (number of times rearing
on the hind limbs) [29].
2.11. Y-Maze Test. Spontaneous alternation behavior in a 𝑌-
maze task was recorded to evaluate spatial referencememory,
according to methods described by Moriguchi et al. [30].
The 𝑌-maze apparatus was made of three identical black
cardboard pieces (𝑙 × 𝑤 × ℎ, 30 × 8 × 10 cm). Mice were
placed at the end of one fixed arm and allowed to move
freely through the maze for 5min. The series of arm entries
was recorded visually.Three consecutive choiceswere defined
as an alternation. The alternation behavior (alternation [%])
was calculated as the ratio of actual alternations to possible
alternations (defined as the number of arm entries minus
two) multiplied by 100.
2.12. Statistical Analysis. Values are expressed as mean ±
standard deviation. The 𝐾𝑖 value of [18F]FAHA, % ID/g
of [18F]FDG of the brain, locomotor, rearing activities,
and alternation (%) before and after drug (cisplatin with
and without SAHA pretreatment) administration were all
investigated using paired 𝑡-test.
3. Results
3.1. PET Study
3.1.1. [18F]FAHAPET. The𝐾𝑖 value of [18F]FAHAof the brain
was significantly increased after cisplatin administration in
Groups A and B (Figures 1(a), 1(b), and 2). In Group C,
there was a lower 𝐾𝑖 value of [18F]FAHA of the brain after
cisplatin administration. The 𝐾𝑖 value of [18F]FAHA of the
brain was not significantly altered after cisplatin with SAHA
administration. Graphical analyses (Patlak plot) and the
multicompartmental pharmacokineticmodel showed similar
quantitative results.
3.1.2. [18F]FDG PET. The accumulated brain radioactivity of
[18F]FDG was significantly decreased after cisplatin admin-
istration in Groups A and B (Figures 1(c) and 3). In Group C,
the accumulated brain radioactivity of [18F]FDGwas not sig-
nificantly changed after cisplatin with SAHA administration
(Figures 1(c) and 3).
3.2. IHC. In the cortex, AH2A, AH3, and AH4 staining
were decreased in a dose-dependent manner with cisplatin in
Groups A and B and were almost equal in Group C compared
to control. The change in AH3 staining was dramatic in the
cerebral cortex. In the hippocampus, AH3 and AH4 staining
were decreased with cisplatin in a dose-dependent manner
in Groups A and B, while they were almost equal in Group C
in the cornu ammonis 3 (CA3) and dentate gyrus compared
to control. The changes of AH2A and AH2B were minimal.
Representative IHC images are shown of AH3 staining in
the cerebral cortex (Figure 4) and hippocampus (Figure 5).
AH3 immunoreactivity in the cortex and hippocampal CA3
is shown in Figure 6. It was significantly lower in the CA3
of Groups A and B compared to the control, whereas Group
C had moderate immunoreactivity in cortex. Hippocampal
immunoreactivity of AH3 showed a similar pattern.
3.3. Animal Behavior. In Group B (cisplatin 4mg/kg), loco-
motor and rearing activity were significantly decreased after
cisplatin administration (72.8 ± 27.0 before cisplatin admin-
istration versus 31.1 ± 16.5 after cisplatin administration, 𝑝 =
0.003; 26.8 ± 13.5 versus 8.4 ± 9.1, 𝑝 = 0.009, resp., Figures
7(a) and 7(b)). Alternation (%) was not significantly changed
(60.1 ± 20.9 versus 70.9 ± 17.0, 𝑝 = 0.300, Figure 7(c)).
In Group C (cisplatin 4mg/kg with SAHA 300mg/kg),
locomotor and rearing activity were significantly decreased
after cisplatin with SAHA administration (94.3 ± 33.6 before
cisplatin with SAHA administration versus 38.5 ± 19.5 after
cisplatin with SAHA administration, 𝑝 = 0.008; 31.0 ± 28.1
versus 14.8 ± 12.3, 𝑝 = 0.048, resp., Figures 7(a) and 7(b)).
The alternation (%) was not significantly changed (60.2±31.3
versus 59.4 ± 26.5, 𝑝 = 0.948, Figure 7(c)).
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Figure 1: Comparison of 𝐾𝑖 values of [18F]FAHA in the brain calculated from multicompartmental pharmacokinetic model and graphical
analyses before and after drug administration. (a) The multicompartmental pharmacokinetic model and (b) Patlak plot both indicated that
𝐾𝑖 was significantly increased after cisplatin administration in Groups A (Cis 2mg/kg) and B (Cis 4mg/kg), but there was no difference in
Group C (Cis 4mg/kg + SAHA 300mg/kg). (c) In Groups A and B, the radioactivity of accumulated [18F]FDG was significantly decreased
after cisplatin administration; however, no differences were observed in Group C. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
4. Discussion
The mechanism of cisplatin-induced neurotoxicity is com-
plicated and has not been fully elucidated. However, the
major neurotoxic mechanism is thought to involve p53, Bcl-
2, caspases 3 and 7, the mitogen-activated protein kinase
family, and the FasR pathway [31–34]. Cisplatin reacts with
DNA, and its cytotoxic effects are due to the generation
of 1,2-intrastrand cross-links between adjacent purines in
d(GpG) and d(ApG) sequences [35, 36]. Although histone
proteins play an important role in DNA transcription, the
participation of HATs and HDACs that form part of the
transcription initiation complex with transcription factors
and regulate histone proteins has not been fully investigated
in the brain. We found that cisplatin treatment was followed
by an increased 𝐾𝑖 value of [18F]FAHA in the brain. In
contrast, the % ID/g of [18F]FDG was decreased in the brain,
and animal behavior was suppressed following cisplatin
administration. This suggests that cisplatin causes excessive
HDAC deacetylation in the brain, subsequently decreasing
the transcription of neuronal DNA. In addition, the IHC
results support our hypothesis of an imbalance between HAT
acetylation andHDACdeacetylation in the brain of cisplatin-
treated mice.
How HDAC inhibitors work with cisplatin in normal
cells has not been elucidated, despite the fact that HDAC
inhibitors could potentially be used as anticancer drugs.
Some reports have stated that HDAC inhibitor pretreatment
inhibits cisplatin-mediated toxicity and promotes renal cell
survival [17, 18]. However, to the best of our knowledge,
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Figure 2: Coronal brain image of [18F]FAHA before and after drug administration. [18F]FAHA PET/CT images summed over the last 10min
of the study (20–30min after [18F]FAHA injection). (a) Anterior, (b)middle, and (c) posterior part of the brain. Brain [18F]FAHA radioactivity
was significantly increased after cisplatin administration.
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Figure 3: Coronal brain image of [18F]FDG before and after drug administration. The [18F]FDG image represents 45–55min after injection.
Image presentation is the same as in Figure 2. Brain [18F]FAHA radioactivity was decreased after cisplatin administration.
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Figure 4: IHC for AH2A, AH2B, AH3, and AH4 in the cerebral cortex. Original magnifications, upper: ×40, lower: ×200 in the parietal
cortex. AH3 staining was suppressed in a dose-dependent manner in the cerebral cortex of mice in Groups A (Cis 2mg/kg) and B (Cis
4mg/kg) and was almost equal in Group C (Cis 4mg/kg + SAHA 300mg/kg) compared with a control mouse. Scale bar, 100 𝜇m.
there has been no report on how HDAC inhibitors work
with cisplatin in the brain. We tested the hypothesis that
HDAC inhibitor pretreatment may block the DNA damage
response in the normal brain and assessed whether it can be
detected using in vivo PET scanning. No significant change
was observed in the mean 𝐾𝑖 value of [18F]FAHA, and six
out of eight mice had lower values compared to the study
before cisplatin with SAHApretreatment. For [18F]FDGPET,
the % ID/g of brain [18F]FDG showed almost no change.
The trend of the change of the 𝐾𝑖 value of [18F]FAHA and
% ID/g of [18F]FDG in the brains of Group C mice was
obviously different from those in Groups A and B. Moreover,
the result of Groups B and C clearly demonstrated that
SAHA pretreatment inhibited the increase in [18F]FAHA
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Figure 5: IHC for AH2A, AH2B, AH3, and AH4 in the hippocampus. Image presentation is the same as in Figure 4. Original magnification,
upper: ×40 in the hippocampus, lower: ×100 in the Ca3. AH3 staining was suppressed in a dose-dependent manner in the CA3 and dentate
gyrus of mice in Groups A (Cis 2mg/kg) and B (Cis 4mg/kg) and was almost equal in Group C (Cis 4mg/kg+ SAHA 300mg/kg), compared
with a control mouse. Scale bar, 100𝜇m.
uptake and the decrease in [18F]FDG uptake in the brains of
cisplatin-treatedmice.This suggests that SAHA blocks excess
HDAC deacetylation and neuronal activity suppression in
the brain following cisplatin administration. The IHC results
also support our hypothesis that SAHA pretreatment blocks
unbalanced excess HDAC deacetylation in the brains of
cisplatin-treated mice. Taken together, our findings indi-
cate that SAHA pretreatment prevents cisplatin-mediated
changes in HAT acetylation and HDAC deacetylation in the
brain.
The fundamental unit of chromatin is the nucleosome,
composed of DNA wrapped around an octamer of four
core histone proteins (H2A, H2B, H3, and H4), each of
which possesses a large number and type of modifiable
residues [3, 37]. However, DNA contains both survival-
associated and death-inducing genes.We do not have enough
Contrast Media & Molecular Imaging 9
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Figure 6: Corresponding values stained with AH3 in the cortex (Figure 4) and hippocampus CA3 (Figure 5). ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
evidence to identify which histones in survival-associated
genes or death-inducing genes reflect [18F]FAHA via changes
in their acetylation/deacetylation balance. However, our PET
results indicate that [18F]FAHA activity seems to be strongly
reflected by histones in survival-associated genes in the brain.
AH3 and AH4 staining are observed during the onset of
neuronal apoptosis in neurodegeneration [38].This is consis-
tent with our finding that AH3 and AH4 show demonstrable
staining in a wide area of the brain in cisplatin-administered
mice.We consider that [18F]FAHAhas the strong potential to
reflect H3 and H4 deacetylation in survival-associated genes
in the brain.
Although SAHApretreatment blocked histone deacetyla-
tion in the brain and contributed to reducing attractive forces
between histone proteins and the DNA phosphate backbone,
resulting in a more relaxed and accessible chromatin struc-
ture, there was no obvious improvement in locomotion. This
may be due to the fact that HDAC inhibitors only affect the
expression of 2% of mammalian genes [2, 39].
5. Conclusion
We performed [18F]FAHA and [18F]FDG PET to investi-
gate changes in HDAC IIa activity in the brains of mice
treated with cisplatin with and without SAHA pretreatment.
[18F]FAHA PET clearly showed higher HDAC IIa activity
after cisplatin administration, and this was blocked by SAHA
pretreatment. In contrast, [18F]FDG uptake was decreased
after cisplatin administration and was blocked by SAHA
pretreatment.Therefore, [18F]FAHA PET could be a useful in
vivo pharmacodynamic biomarker of cisplatin neurotoxicity.
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Figure 7: Animal behavior test: (a) locomotion, (b) rearing activity, and (c) alteration. Locomotion and rearing activity decreased after
cisplatin administration with and without SAHA pretreatment. Alternation (%) was not significantly changed after cisplatin administration
with and without SAHA pretreatment. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01.
divided to 3 groups and received intraperitoneal doses of
cisplatin 2mg/kg (GroupA) or 4mg/kg (GroupB) or 4mg/kg
with SAHA 300 mg/kg (Group C) (details in the Materials
and Methods). PET/CT imaging was performed before and
after drug administration. Additionally, Groups B and Cwere
tested with behavioral assays to assess cognitive function
one day before the first and second PET/CT studies. After
PET/CT imaging, the results were validated by IHC of brain
tissue sections.
Supplementary 2. Supplementary Figure S2: illustration of
a multicompartmental pharmacokinetic model with two
simultaneous blood input functions for [18F]FAHA and
[18F]FACE that was used to estimate the 𝐾𝑖 values of
[18F]FAHA in this study.
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